Skip to search formSkip to main contentSkip to account menu

EMD 273063 antibody, human

Known as: Hu 14.18/IL - 2 Fusion Protein, hu14.18-interleukin-2 fusion protein, EMD 273063 
A recombinant protein consisting of the hu14.18 monoclonal antibody fused to the cytokine interleukin-2 (IL2) with potential antineoplastic activity… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA PURPOSE: Use “off the shelf” reagents to… 
2015
2015
We have identified a cooperative interaction between radiation and intratumoral injection of anti-GD2 immunocytokine (hu14.18-IL2… 
2014
2014
9044 Background: Phase I testing of the hu14.18-IL2 immunocytokine (IC), a mAb reactive with GD2 disialoganglioside, linked to… 
2013
2013
Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC Immunotherapy of neuroblastoma with anti-GD2… 
2012
2012
Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL Introduction: Hu14.18-IL2 (APN301, Apeiron… 
2010
2010
Response to immunocytokine (IC) therapy is dependent on natural killer (NK) cells in murine neuroblastoma (NBL) models… 
Review
2008
Review
2008
3002 Background: The hu14.18-IL2 fusion protein consists of IL2 linked to a humanized mAb that recognizes the GD2… 
2008
2008
9039 Background: The hu14.18-IL2 immunocytokine consists of a humanized anti-GD2 monoclonal antibody linked to IL2. It has potent… 
2001
2001
Immuntherapie von Krebs hat eine lange Geschichte. Die bisher erfolgreichsten Ansätze beruhen auf Antikörpern (AK) mit einer…